5300-03-8
5300-03-8 結(jié)構(gòu)式
基本信息
異維A酸雜質(zhì)4
9-順式維甲酸
9-順式視黃酸
9-CIS維甲酸
維A酸EP雜質(zhì)D
9-順式視黃醇酸
異維A酸EP雜質(zhì)D
異維甲酸EP雜質(zhì)D
9-順-視黃酸 [干冰運(yùn)輸,需加收額外費(fèi)用]
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
toxic compounds or compounds which causing chronic effects
Repr. 1B
Skin Irrit. 2
STOT SE 3
常見問題列表
異維A酸EP雜質(zhì)D是異維A酸合成過程中產(chǎn)生產(chǎn)生的雜質(zhì)，又名阿利維甲酸，是治療皮膚病領(lǐng)域的重要藥物，是全反式維甲酸(式II，化學(xué)名：3，7-二甲基-9-(2，6，6-三甲基環(huán)己烯-1-基)-2E，4E，6E，8E-全反式壬四烯酸)的9-順異構(gòu)體。
異維A酸EP雜質(zhì)D（式I化合物）的制備：在氮?dú)獗Ｗo(hù)下，往反應(yīng)瓶中加入乙醇2L、全反式維甲酸100g，攪拌，然后升溫至50～55℃，加入PdCl289mg。反應(yīng)1.5h后，經(jīng)HPLC檢測產(chǎn)物純度為21％。反應(yīng)液緩慢降溫至0～5℃，保溫180分鐘，抽濾；濾液加入另一干凈反應(yīng)瓶中，繼續(xù)降溫至-10～-6℃，保溫20分鐘，抽濾，得到產(chǎn)物異維A酸EP雜質(zhì)D 12.1g，總收率12.1％，HPLC純度99.60％。以全反式維甲酸為原料，采用鈀化合物催化，在普通的工業(yè)級(jí)有機(jī)溶劑中可得到阿利維甲酸。方法操作簡便，成本低，條件可控，便于工業(yè)生產(chǎn)；經(jīng)過后處理步驟后，可得到純度99％以上的阿利維甲酸，產(chǎn)物收率達(dá)到12％以上，具有較高的應(yīng)用價(jià)值。
9-cis-Retinoic acid (1-10 μM; 0-5 days; CA 9-22 and NA cells) treatment significantly decreases proliferation in a dose-dependent manner in CA 9-22 and NA cells.
9-cis-Retinoic acid (1 μM; 24 hours) treatment significantly increases PPARγ functional activity by >200% in CA 9-22 and NA aerodigestive cells.
9-cis-Retinoic acid treatment results in the formation of a nuclear PPARγ-RXRα heterodimer supershift complex in CA 9-22 cells.
9-cis-Retinoic acid inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma (CTCL) in a dose-dependent and time-dependent manner. 9-cis-Retinoic acid also induces G0/G1 cell cycle arrest by downregulation of cyclin D1. 9-cis-Retinoic acid significantly decreases phosphorylation of JAK1, STAT3, and STAT5 and downregulated Bcl-xL and cyclin D1.
Cell Proliferation Assay
| Cell Line: | CA 9-22 and NA cells |
| Concentration: | 1 μM, 10 μM |
| Incubation Time: | 0 day, 1 day, 3 days, 5 days |
| Result: | Significantly decreased proliferation. |
9-cis-Retinoic acid (1 mg/kg; intravenous injection; daily; for 10 days; male C57BL/6J mice) treatment significantly decreases the serum ALT and AST level, alleviates hepatic necrosis of the bile duct ligation (BDL)-mice.
| Animal Model: | Male C57BL/6J mice (6-8 weeks; 19-22 g) treatment with bile duct ligated |
| Dosage: | 1 mg/kg |
| Administration: | Intravenous injection; daily; for 10 days |
| Result: | Significantly decreased the serum ALT and AST level, alleviated hepatic necrosis. |